Chimerix, Inc. - Common Stock (NQ:CMRX)

8.540 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Chimerix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

July 28, 2025

Via Investor Brand Network

Topics Artificial Intelligence

Top 3 Health Care Stocks That May Crash In Q2 ↗

April 07, 2025

Via Benzinga

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

March 21, 2025

From Chimerix, Inc.

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders

March 12, 2025

From Halper Sadeh LLC

Via GlobeNewswire

This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

March 06, 2025

Via Benzinga

Demystifying Chimerix: Insights From 4 Analyst Reviews ↗

March 05, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)

March 11, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders

March 11, 2025

From Halper Sadeh LLC

Via GlobeNewswire

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

March 10, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts ↗

December 30, 2024

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders

March 08, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 07, 2025

From Chimerix, Inc.

Via GlobeNewswire

CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders

March 07, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Unusual volume stocks are being observed in Thursday's session. ↗

March 06, 2025

Which stocks have an unusual volume on Thursday?

Via Chartmill

Here are the top movers in Wednesday's session. ↗

March 05, 2025

Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

These stocks are making the most noise in today's session. ↗

March 05, 2025

Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume!

Via Chartmill

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders

March 05, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Which stocks are experiencing notable movement on Wednesday? ↗

March 05, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)

March 05, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Wednesday's session: gap up and gap down stocks ↗

March 05, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

These stocks that are showing activity before the opening bell on Wednesday. ↗

March 05, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline ↗

March 05, 2025

Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline.

Via Benzinga

CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders

March 05, 2025

From Halper Sadeh LLC

Via Business Wire

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 05, 2025

From Chimerix, Inc.; Jazz Pharmaceuticals plc

Via GlobeNewswire

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2025

From Chimerix, Inc.

Via GlobeNewswire

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

February 18, 2025

From Chimerix, Inc.

Via GlobeNewswire

Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

January 29, 2025

From Chimerix, Inc.

Via GlobeNewswire

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 24, 2025

From Chimerix, Inc.

Via GlobeNewswire

Chimerix to Speak Today at The White House Cancer Moonshot Forum

January 13, 2025

Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development

From Chimerix, Inc.

Via GlobeNewswire

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

December 30, 2024

Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility

From Chimerix, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.